These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2126028)

  • 1. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
    Ginsberg GM; Tulchinsky TH
    J Epidemiol Community Health; 1990 Dec; 44(4):274-80. PubMed ID: 2126028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles control in developing and developed countries: the case for a two-dose policy.
    Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
    Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles in Israel, the West Bank, and Gaza: continuing incidence and the case for a new eradication strategy.
    Tulchinsky TH; Abed Y; Ginsberg G; Shaheen S; Friedman JB; Schoenbaum ML; Slater PE
    Rev Infect Dis; 1990; 12(5):951-8. PubMed ID: 2237137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of measles in Israel: short- and long-term intervention strategies.
    Tulchinsky TH
    Isr J Med Sci; 1991 Jan; 27(1):22-9. PubMed ID: 1995496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles containment in Israel.
    Slater PE
    Isr J Med Sci; 1991 Jan; 27(1):19-21. PubMed ID: 1995495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
    Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
    Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity.
    Ginsber GM; Slater PE; Shouval D
    J Hepatol; 2001 Jan; 34(1):92-9. PubMed ID: 11211913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Costs and benefits of measles vaccination].
    Ambrosch F; Wiedermann G; Harasek G
    Fortschr Med; 1978 Feb; 96(8):409-14. PubMed ID: 415953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Shouval D
    J Epidemiol Community Health; 1992 Dec; 46(6):587-94. PubMed ID: 1494073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles immunity in Israeli young adults: effects of second immunization at 18 years of age.
    Olsha M; Mendelson E; Shohat T; Cohen D; Duvdevani P; Lerman Y; Danon YL
    Isr J Med Sci; 1994 Aug; 30(8):596-9. PubMed ID: 8045739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
    Takahashi K; Ohkusa Y; Kim JY
    BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
    Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
    Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles during the Gulf War: a public health threat in Israel, the West Bank, and Gaza.
    Tulchinsky TH; Belmaker I; Raabi S; Acker C; Arbeli Y; Lobel R; Abed Y; Toubassi N; Goldberg E; Slater PE
    Public Health Rev; 1992-1993; 20(3-4):285-96. PubMed ID: 1343365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.
    Ginsberg GM; Kassis I; Dagan R
    J Epidemiol Community Health; 1993 Dec; 47(6):485-90. PubMed ID: 8120505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of supplementary immunization for measles in India.
    Dabral M
    Indian Pediatr; 2009 Nov; 46(11):957-62. PubMed ID: 19578225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.